69 results on '"E. Destefanis"'
Search Results
2. sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tumour resistance in combination with Bortezomib
- Author
-
Arianna Giacomini, Patrizia Perri, Monica Loi, Mirco Ponzoni, Pamela Becherini, Laura Emionite, D. Di Paolo, E. Destefanis, Chiara Brignole, Irene Cossu, M. Cilli, Fabio Pastorino, and Francesca Piaggio
- Subjects
medicine.medical_treatment ,Mice, Nude ,Pharmaceutical Science ,TRAIL ,Antineoplastic Agents ,Apoptosis ,Pharmacology ,Bortezomib ,TNF-Related Apoptosis-Inducing Ligand ,Mice ,Neuroblastoma ,In vivo ,Cell Line, Tumor ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Animals ,Humans ,Combination therapies ,Liposomes ,business.industry ,medicine.disease ,Boronic Acids ,In vitro ,Pyrazines ,Proteasome inhibitor ,Female ,Nanocarriers ,business ,Adjuvant ,medicine.drug - Abstract
Neuroblastoma (NB), the most common and deadly extracranial solid tumour of childhood, represents a challenging in paediatric oncology. Soluble tumour necrosis factor (TNF)-related apoptosis-inducing ligand (sTRAIL) is a cancer cell-specific molecule exerting remarkable anti-tumour activities against paediatric malignancies both in vitro and in preclinical settings. However, due to its too fast elimination and to the undesired related side effects, the improvement of sTRAIL in vivo bioavailability and the specific delivery to the tumour is mandatory for increasing its therapeutic efficacy. In this manuscript, we developed an innovative pegylated liposomal formulation carrying the sTRAIL at the outer surface (sTRAIL-SL) with the intent to improve its serum half-life and increase its efficacy in vivo, while reducing side effects. Furthermore, the possibility to combine sTRAIL-SL with the proteasome inhibitor Bortezomib (BTZ) was investigated, being BTZ able to sensitize tumour cells toward TRAIL-induced apoptosis. We demonstrated that sTRAIL preserved and improved its anti-tumour activity when coupled to nanocarriers. Moreover, sTRAIL-SL ameliorated its PK profile in blood allowing sTRAIL to exert a more potent anti-tumour activity, which led, upon BTZ priming, to a statistically significant enhanced life spans in two models of sTRAIL-resistant NB-bearing mice. Finally, mechanistic studies indicated that the combination of sTRAIL with BTZ sensitized sTRAIL-resistant NB tumour cells to sTRAIL-induced cell death, both in vitro and in vivo, through the Akt/GSK3/β-catenin axis-dependent mechanism. In conclusion, our results suggest that sTRAIL-SL might be an efficient vehicle for sTRAIL delivery and that its use in clinic, in combination with BTZ, might represent an adjuvant strategy for the treatment of stage IV, sTRAIL-resistant, NB patients.
- Published
- 2014
- Full Text
- View/download PDF
3. Cryptogenic cerebral infarction in a young patient with very high lipoprotein(a) serum level as the only risk factor
- Author
-
A. Lentini, Paolo Cerrato, Giovanni Bosco, Paolo Fornengo, E. Destefanis, and Mariagiovanna Caprioli
- Subjects
Adult ,Male ,medicine.medical_specialty ,Neurology ,Apolipoprotein B ,Dermatology ,Risk Factors ,Internal medicine ,medicine ,Humans ,Myocardial infarction ,Risk factor ,Stroke ,biology ,business.industry ,Cerebral infarction ,Cerebral Infarction ,General Medicine ,Lipoprotein(a) ,medicine.disease ,Magnetic Resonance Imaging ,Psychiatry and Mental health ,biology.protein ,Cardiology ,lipids (amino acids, peptides, and proteins) ,Neurology (clinical) ,business ,Lipoprotein - Abstract
Lipoprotein(a) [Lp(a)] is a plasma lipoprotein that consists of a low-density lipoprotein (LDL)-like particle containing APO B-100 and apolipoprotein(a), linked by a disulphide bridge. There is evidence that higher serum level of Lp(a) is a predictor of various vascular diseases, such as myocardial infarction, coronary stenosis, re-occlusion of aortocoronary bypass vein grafts, peripheral atherosclerosis and cerebral infarction [1-4]. We describe a young man with a cryptogenic stroke with very high serum level of Lp(a) as the only vascular risk factor.
- Published
- 2007
- Full Text
- View/download PDF
4. Vertebral artery dissection complicated by basilar artery occlusion successfully treated with intra-arterial thrombolysis: three case reports
- Author
-
Paolo Cerrato, Edo Bottacchi, Mariagiovanna Caprioli, A. Lentini, E. Destefanis, Giovanni Bosco, Gianni Boris Bradac, Giovanni Corso, D. Daniele, Maurizio Berardino, and Mauro Bergui
- Subjects
Adult ,Male ,medicine.medical_specialty ,Cervical Artery ,Vertebral artery dissection ,medicine.medical_treatment ,Dermatology ,Dissection (medical) ,Brain Ischemia ,Embolus ,Thromboembolism ,medicine ,Humans ,Thrombolytic Therapy ,cardiovascular diseases ,Thrombus ,Stroke ,Vertebral Artery Dissection ,Arterial dissection ,business.industry ,General Medicine ,Thrombolysis ,Cerebral Infarction ,Middle Aged ,medicine.disease ,Surgery ,Cerebral Angiography ,Psychiatry and Mental health ,Injections, Intra-Arterial ,Basilar Artery ,Tissue Plasminogen Activator ,Female ,Neurology (clinical) ,Radiology ,business - Abstract
Cervical artery dissection is an important cause of stroke in young patients and accounts of 10%–20% of stroke or TIA in patients aged less than 50 years. Basilar artery occlusion (BAO) is an infrequent cause of acute stroke, which invariably leads to death or long-term disability if not recanalized. We describe three patients with BAO caused by vertebral dissection, successfully treated with intra-arterial thrombolysis. The lysis of the occluding embolus was obtained by injection of the thrombolytic drug directly or near the thrombus without haemor-rhagic complications. Our cases confirm the safety and efficacy of intra-arterial thrombolysis in patients with BAO due to a vertebral artery dissection.
- Published
- 2007
5. Atherosclerotic adult Moya-Moya disease in a patient with hyperhomocysteinaemia
- Author
-
E. Destefanis, Mauro Bergui, A. Lentini, Mariagiovanna Caprioli, Gianni Boris Bradac, Paolo Cerrato, M. Grasso, and Giovanni Bosco
- Subjects
Male ,medicine.medical_specialty ,Neurology ,Lacunar stroke ,Hyperhomocysteinemia ,Infarction ,Dermatology ,Internal medicine ,medicine.artery ,Occlusion ,medicine ,Humans ,cardiovascular diseases ,Neuroradiology ,business.industry ,General Medicine ,Middle Aged ,Atherosclerosis ,medicine.disease ,Radiography ,Psychiatry and Mental health ,Stenosis ,Cardiology ,Neurology (clinical) ,Neurosurgery ,Moyamoya Disease ,Internal carotid artery ,business ,Magnetic Resonance Angiography - Abstract
Moya-Moya is a rare cerebrovascular occlusive disease characterized by bilateral stenosis or occlusion at the terminal portion of the internal carotid artery and abnormal vascular network at the base of the brain, named "moya-moya". In children, Moya-Moya disease usually presents with ischemic cerebrovascular events, mainly TIA or lacunar stroke, leading to mental deterioration. In adults, especially in females, it presents with intracranial haemorrhages. We describe the case of an adult patient with an atherosclerotic Moya-Moya disease which presented with a cerebral borderzone infarction.
- Published
- 2007
6. Recurrent cerebrovascular ischaemic events in patients with interatrial septal abnormalities: a follow-up study
- Author
-
Fulvio Orzan, Daniele Imperiale, Giovanni Bosco, G. P. Trevi, Lorenzo Priano, Bruno Bergamasco, A. M. Villar, Paolo Cerrato, E. Destefanis, and M. Ribezzo
- Subjects
Adult ,Male ,Risk ,medicine.medical_specialty ,Adolescent ,Population ,Dermatology ,Heart Septal Defects, Atrial ,Recurrence ,Internal medicine ,medicine ,Humans ,cardiovascular diseases ,Heart Aneurysm ,education ,Echocardiography ,Female ,Follow-Up Studies ,Heart Septal Defects ,Atrial ,Ischemic Attack ,Transient ,Middle Aged ,Proportional Hazards Models ,Retrospective Studies ,Survival Analysis ,Stroke ,education.field_of_study ,Heart septal defect ,business.industry ,Retrospective cohort study ,General Medicine ,medicine.disease ,Surgery ,Psychiatry and Mental health ,Embolism ,Ischemic Attack, Transient ,Patent foramen ovale ,Cardiology ,Neurology (clinical) ,Neurosurgery ,business - Abstract
The aim of this study was to evaluate the risk of recurrent ischaemic cerebrovascular events (stroke or transient ischaemic attack (TIA)) in patients with patent foramen ovale (PFO) or atrial septal aneurysm (ASA) treated with different therapeutic regimens. We enrolled 86 patients aged 18-60 years with an unexplained ischaemic stroke or TIA referred to our inpatient department in the period May 1994-December 1999. Follow-up lasted until April 2003. Patients were excluded if the stroke or TIA was related to large-artery atherosclerosis, small artery occlusion, major cardiac sources of embolism or other uncommon causes. During a follow-up (mean+/-SD) of 64.1+/-28.8 months (range 8.1-105.6) a recurrent ischaemic cerebrovascular event occurred in 11/86 patients (12.8%) (5 TIA and 6 strokes). Eight events (4 TIA, 4 strokes) occurred in the 59 patients with PFO alone, three (1 TIA, 2 strokes) in the 21 with PFO plus ASA and none in the 6 patients with ASA alone. In the overall population the cumulative risk of recurrent stroke/TIA was 1.2% at 2 years, 5.5% at 4 years, 7.6% at 6 years and 23.6% at 8 years, and was similar in patients with PFO alone vs. patients with PFO plus ASA (9.0% vs. 6.1% at 6 years, 26.0% vs. 23.1% at 8 years; p0.05). Nine cerebral ischaemic events (4 TIA, 5 strokes) occurred in the 48 patients treated with antiplatelet drugs (7 in patients with PFO, 2 in patients with PFO plus ASA), and two (1 TIA, 1 stroke) in the 17 patients treated with oral anticoagulants (1 with PFO, 1 with PFO plus ASA). No events occurred in patients submitted to transcatheteral closure.
- Published
- 2005
7. Gait and bilateral limb ataxia as isolated feature of a lower midbrain tegmental infarction
- Author
-
Rossella Colonna, Giovanni Bosco, Paolo Cerrato, A. Lentini, E. Destefanis, Mariagiovanna Caprioli, and Mauro Bergui
- Subjects
Ataxia ,Palatal myoclonus ,medicine.diagnostic_test ,Cerebellar ataxia ,business.industry ,Limb ataxia ,Infarction ,Neurological examination ,Anatomy ,medicine.disease ,Neurology ,Dysmetria ,medicine ,Neurology (clinical) ,Midbrain tegmentum ,medicine.symptom ,business - Abstract
Sirs: The clinical picture of midbrain infarction is dominated by third-nerve palsy, conjugate or disconjugate gaze impairment, contralateral motor and sensory deficit and homolateral or contralateral limb ataxia [1–3]. Among various mesencephalic syndromes of vascular origin, those related to the lower midbrain lesion are rare [2, 3]. We describe a patient with an isolated lower tegmental midbrain infarction, with gait and bilateral limb ataxia as isolated features. A 71-year-old man complained of dizziness, imbalance, slight hypersomnolence, and bilateral clumsiness of arms and legs. There was a worsening of symptoms and 12 hours later at admission neurological examination revealed slight hypersomnolence, dysartric speech and pronounced gait and bilateral limb ataxia. The NIHSS score was four. The patient walked with a wide-based, staggering gait without tendency to deviate to one side. The stance was on a broad base with impossibility standing with their feet together or in tandem position. Romberg sign was absent. At the finger-to-nose and at the heel-to-shine tests important dysmetria was present. The movement path of the limbs was erratic with relevant hypermetria. Rapid alternating movements were irregular bilaterally. The rest of the neurological examination was normal. One year before he suffered from an anterior circulation infarction involving the frontal branches of the right middle cerebral artery, without any residual deficit. Regarding conventional vascular risk factors, the patient suffered from hypertension and non-valvular atrial fibrillation. He was taking oral anticoagulants, with INR value ranging between 2 and 3. Non contrast cranial CT showed only the previous right frontal infarction. Five days later brain MRI revealed a small ischemic lesion in the middle tegmental portion of the lower midbrain (Fig 1 A–C); multiple silent small lacunar infarctions were present in the white matter bilaterally. Extracranial duplex ultrasonography and MR-angiography of carotid, vertebral and basilar arteries were normal. Transthoracic and transoesophageal echocardiography failed in revealing intra-cardiac thrombi. Eight-months later gait and bilateral limb ataxia and dysartria were the isolated and persistent neurological deficits. Palatal myoclonus was absent and the modified Rankin Scale was 3. Our patient presented an infarction in the middle portion of the midbrain tegmentum, with gait and bilateral cerebellar limb ataxia as dominant and persistent symptoms. The vascularization of the midbrain regions is complex, and the region close to the midline is supplied by the paramedian branches from the basilar artery (Fig 1D). Generally, in midbrain infarction the cerebellar ataxia is overshadowed by upper-midbrain and thalamic-subthalamic signs [1–2]. A tetra-ataxia has been reported in patients with midbrain infarction [1–6] but in none of them it was the isolated feature. In these cases the bilateral ataxia was associated to other neurological deficits, such as hemiparesis, dysphagia, dysphonia, eye-movement disorders or palatal myoclonus. Moreover, a bilateral ataxia was the sole manifestation of a rostral pontine tegmental infarction [7] and in patients with heat stroke [8]. In our patient the clinical picture may be considered a partial form of the Wernekink commissure syndrome where bilateral ataxia is associated to ocular abnormalities and palatal myoclonus. Indeed oculomotor deficit and delayed palatal myoclonus were absent and cerebellar signs were isolated except for the transient hypersomnolence related to the involvement of the reticular formation located dorsally to the superior cerebellar peduncles Supported by Piedmont Region, Ricerea Scientifica Applicata 2004.
- Published
- 2008
- Full Text
- View/download PDF
8. Hypogeusia and hearing loss in a patient with an inferior collicular infarction
- Author
-
Paolo Cerrato, A. Lentini, Paolo Benna, Maria Grazia Grasso, Bruno Bergamasco, Giovanni Bosco, E. Destefanis, Mauro Bergui, C. Baima, and C. Azzaro
- Subjects
Male ,medicine.medical_specialty ,Brain Stem Infarctions ,Ataxia ,Hearing loss ,Audiology ,Brain Ischemia ,Tongue ,Neural Pathways ,Vertebrobasilar Insufficiency ,medicine ,Humans ,Hearing Loss, Central ,Palsy ,business.industry ,Hypogeusia ,Limb ataxia ,Hypoesthesia ,Middle Aged ,Ageusia ,Magnetic Resonance Imaging ,Inferior Colliculi ,medicine.anatomical_structure ,Trigeminal Nerve Diseases ,Face ,Sensation Disorders ,Neurology (clinical) ,medicine.symptom ,Tomography, X-Ray Computed ,business ,Brain Stem - Abstract
Various vascular syndromes have been described in patients with midbrain infarction.1,2 The clinical picture is dominated by third-nerve palsy, conjugate or disconjugate gaze impairment, contralateral motor and sensory deficit and homolateral or contralateral limb ataxia. We describe a patient with a pontomesencephalic tegmental infarction with hearing loss and hypogeusia as dominant features. A 52-year-old man had dizziness and loss of taste while eating dinner. The next morning upon awakening, he developed sensory changes of the left half of his face, clumsiness of the right arm and leg, and sensation of bilateral ear wadding. At admission, neurologic examination revealed right limb ataxia, decreased pinprick and touch sensation over the left half of his face, and bilateral hypoacusia, more marked on the left side. There was a marked diminution of taste on the left side of the tongue. His taste was examined by application of 0.5 M NaCl, 10% glucose, 0.2 M acetic acid, and 0.02 M quinine. The rest of the neurologic examination was normal. Limb ataxia and left face hypoesthesia gradually disappeared, and 10 days later only left tongue hypogeusia …
- Published
- 2005
- Full Text
- View/download PDF
9. [Cortisone and streptomycin in the treatment of experimental tuberculosis; protein level and Middlebrook-Dubos reaction]
- Author
-
G, CONTERNO, E, DESTEFANIS, A M, PELOCCHINO, and G, PESCETTI
- Subjects
Cortisone ,Streptomycin ,Tuberculosis ,Blood Proteins - Published
- 1956
10. [Complement power and its fractions in the cerebrospinal fluid in tuberculous meningitis]
- Author
-
D, CASTELLI and E, DESTEFANIS
- Subjects
Tuberculosis, Meningeal ,Humans ,Tuberculosis ,Cerebrospinal Fluid - Published
- 1956
11. [First clinical observations on the antituberculous activity of a compound derived from the salification of streptomycin and Congo red]
- Author
-
G, PESCETTI and E, DESTEFANIS
- Subjects
Aniline Compounds ,Tuberculosis, Meningeal ,Streptomycin ,Humans ,Tuberculosis ,Congo Red ,Coloring Agents ,Tuberculosis, Pulmonary - Published
- 1953
12. [Behavior of medullar peroxidases in brucellosis]
- Author
-
E, DESTEFANIS and V, PRATO
- Subjects
Peroxidases ,Bone Marrow ,Humans ,Oxidoreductases ,Brucellosis - Published
- 1956
13. [Small doses of cortisone with salicylates and antibiotics in acute articular rheumatism]
- Author
-
M, POLI, E, DESTEFANIS, and G, CONTERNO
- Subjects
Cortisone ,Humans ,Rheumatic Fever ,Salicylates ,Anti-Bacterial Agents - Published
- 1954
14. [Determination of a new streptomycin salt derivative with Congo red]
- Author
-
G, PESCETTI and E, DESTEFANIS
- Subjects
Aniline Compounds ,Streptomycin ,Humans ,Congo Red ,Coloring Agents - Published
- 1953
15. [Congenital aortic coarctation; clinical study]
- Author
-
E, DESTEFANIS
- Subjects
Humans ,Aorta ,Aortic Coarctation - Published
- 1952
16. [Diagnostic value of anti- streptolysin O]
- Author
-
M, POLI, E, DESTEFANIS, F, BALZOLA, G, CONTERNO, R, SIMONETTA, and L, DUGHERA
- Subjects
Bacterial Proteins ,Rheumatic Diseases ,Streptolysins ,Humans - Published
- 1955
17. [Experimental research on the association of Congo Red and streptomycin, combined in a salt of well-defined chemical structure, in tuberculosis]
- Author
-
G, PESCETTI and E, DESTEFANIS
- Subjects
Aniline Compounds ,Streptomycin ,Humans ,Tuberculosis ,Congo Red ,Coloring Agents - Published
- 1952
18. On the anti-allergic action of nicotamide
- Author
-
D, CASTELLI and E, DESTEFANIS
- Subjects
Nicotinic Acids ,Humans ,Niacin - Published
- 1949
19. [The treatment of bacterial intestinal infections with streptomycin salt and Congo red]
- Author
-
G, PESCETTI, G, BIGLINO, and E, DESTEFANIS
- Subjects
Salmonella Infections ,Streptomycin ,Humans ,Congo Red ,Bacterial Infections ,Coloring Agents - Published
- 1954
20. [New anti-tuberculosis compound from the salification of streptomycin with congo red]
- Author
-
G, PESCETTI and E, DESTEFANIS
- Subjects
Streptomycin ,Tuberculosis ,Congo Red - Published
- 1952
21. Intravenous vaccinotherapy of the Melitense infection
- Author
-
E, DESTEFANIS
- Subjects
Brucellosis - Published
- 1948
22. [Opsonin and tropine; old and new concepts; personal contributions; their behavior in various diseases]
- Author
-
D, CASTELLI and E, DESTEFANIS
- Subjects
Atropine ,Phagocytosis ,Humans ,Antigens ,Opsonin Proteins ,Antibodies ,Tropanes - Published
- 1955
23. [Absorption of aerosolized antibiotics: delayed absorption and reduced renal elimination of penicillin]
- Author
-
E, ANGLESIO and E, DESTEFANIS
- Subjects
Renal Elimination ,Humans ,Penicillins ,Anti-Bacterial Agents - Published
- 1949
24. [Behavior and determination of a new anti-tuberculous compound resulting from salification of streptomycin with Congo red in blood and in tissue of the tuberculous]
- Author
-
G, PESCETTI and E, DESTEFANIS
- Subjects
Aniline Compounds ,Streptomycin ,Humans ,Tuberculosis ,Congo Red ,Coloring Agents - Published
- 1953
25. [Chloromycetin therapy of the Salmonella typhimurium infection]
- Author
-
E, DESTEFANIS
- Subjects
Salmonella typhimurium ,Chloramphenicol ,Humans - Published
- 1951
26. [Absorption of aerosol antibiotics]
- Author
-
E, ANGLESIO and E, DESTEFANIS
- Subjects
Aerosols ,Humans ,Dermatologic Agents ,Anti-Bacterial Agents - Published
- 1949
27. Measurement of the branching fraction for psi(3770) -> gamma chi c0
- Author
-
Ablikim, M, Achasov, MN, Ai, XC, Albayrak, O, Albrecht, M, Ambrose, DJ, Amoroso, A, An, FF, An, Q, Bai, JZ, Ferroli, RB, Ban, Y, Bennett, DW, Bennett, JV, Bertani, M, Bettoni, D, Bian, JM, Bianchi, E, Boger, E, Boyko, I, Briere, RA, Cai, H, Cai, X, Cakir, O, Calcaterra, A, Cao, GF, Cetin, SA, Chang, JF, Chelkov, G, Chen, G, Chen, HS, Chen, HY, Chen, JC, Chen, ML, Chen, SJ, Chen, X, Chen, XR, Chen, YB, Cheng, HP, Chu, XK, Cibinetto, G, Dai, HL, Dai, JP, Dbeyssi, A, Dedovich, D, Deng, ZY, Denig, A, Denysenko, I, Destefanis, M, De Mori, F, Ding, Y, Dong, C, Dong, J, Dong, LY, Dong, MY, Dou, ZL, Du, SX, Duan, PF, Eren, EE, Fan, JZ, Fang, J, Fang, SS, Fang, X, Fang, Y, Farinelli, R, Fava, L, Fedorov, O, Feldbauer, F, Felici, G, Feng, CQ, Fioravanti, E, Fritsch, M, Fu, CD, Gao, Q, Gao, XL, Gao, XY, Gao, Y, Gao, Z, Garzia, I, Goetzen, K, Gong, L, Gong, WX, Gradl, W, Greco, M, Gu, MH, Gu, YT, Guan, YH, Guo, AQ, Guo, LB, Guo, Y, Guo, YP, Haddadi, Z, Hafner, A, Han, S, Hao, XQ, Harris, FA, He, KL, Held, T, Heng, YK, Hou, ZL, Hu, C, Hu, HM, Hu, JF, Hu, T, Hu, Y, Huang, GS, Huang, JS, Huang, XT, Huang, Y, Hussain, T, Ji, Q, Ji, QP, Ji, XB, Ji, XL, Jiang, LW, Jiang, XS, Jiang, XY, Jiao, JB, Jiao, Z, Jin, DP, Jin, S, Johansson, T, Julin, A, Kalantar-Nayestanaki, N, Kang, XL, Kang, XS, Kavatsyuk, M, Ke, BC, Kiese, R, Kliemt, R, Kloss, B, Kolcu, OB, Kopf, B, Kornicer, M, Kuehn, W, Kupsc, A, Lange, JS, Lara, M, Larin, R, Leng, C, Li, C, Li, DM, Li, F, Li, FY, Li, G, Li, HB, Li, JC, Li, J, Li, K, Li, L, Li, PR, Li, QY, Li, T, Li, WD, Li, WG, Li, XL, Li, XM, Li, XN, Li, XQ, Li, ZB, Liang, H, Liang, YF, Liang, YT, Liao, GR, Lin, DX, Liu, BJ, Liu, CX, Liu, D, Liu, FH, Liu, F, Liu, HB, Liu, HH, Liu, HM, Liu, J, Liu, JB, Liu, JP, Liu, JY, Liu, K, Liu, KY, Liu, LD, Liu, PL, Liu, Q, Liu, SB, Liu, X, Liu, YB, Liu, ZA, Liu, Z, Loehner, H, Lou, XC, Lu, HJ, Lu, JG, Lu, Y, Lu, YP, Luo, CL, Luo, MX, Luo, T, Luo, XL, Lyu, XR, Ma, FC, Ma, HL, Ma, LL, Ma, QM, Ma, T, Ma, XN, Ma, XY, Ma, YM, Maas, FE, Maggiura, M, Mao, YJ, Mao, ZP, Marcello, S, Messchendorp, JG, Min, J, Mitchell, RE, Mo, XH, Mo, YJ, Morales, CM, Muchnoi, NY, Muramatsu, H, Nefedov, Y, Nerling, F, Nikolaev, IB, Ning, Z, Nisar, S, Niu, SL, Niu, XY, Olsen, SL, Ouyang, Q, Pacetti, S, Pan, Y, Patteri, R, Pelizaeus, M, Peng, HP, Peters, K, Pettersson, J, Ping, JL, Ping, RG, Poling, R, Prasad, V, Qi, HR, Qi, M, Qian, S, Qiao, CF, Qin, LQ, Qin, N, Qin, XS, Qin, ZH, Qiu, JF, Rashid, KH, Redmer, CF, Ripka, M, Rong, G, Rosner, C, Ruan, XD, Santoro, V, Sarantsev, A, Savrie, M, Schoenning, K, Schumann, S, Shan, W, Shao, M, Shen, CP, Shen, PX, Shen, XY, Sheng, HY, Song, WM, Song, XY, Sosio, S, Spataro, S, Sun, GX, Sun, JF, Sun, SS, Sun, YJ, Sun, YZ, Sun, ZJ, Sun, ZT, Tang, CJ, Tang, X, Tapan, I, Thorndike, EH, Tiemens, M, Ullrich, M, Uman, I, Varner, GS, Wang, B, Wang, BL, Wang, D, Wang, DY, Wang, K, Wang, LL, Wang, LS, Wang, M, Wang, R, Wang, PL, Wang, SG, Wang, W, Wang, WP, Wang, XF, Wang, YD, Wang, YF, Wang, YQ, Wang, Z, Wang, ZG, Wang, ZH, Wang, ZY, Weber, T, Wei, DH, Wei, JB, Weidenkaff, R, Wen, SP, Wiedner, U, Wolke, M, Wu, LH, Wu, Z, Xia, L, Xia, LG, Xia, Y, Xiao, D, Xiao, H, Xiao, ZJ, Xie, YG, Xiu, QL, Xu, GF, Xu, L, Xu, QJ, Xu, QN, Xu, XP, Yan, L, Yan, WB, Yan, WC, Yan, YH, Yang, HJ, Yang, HX, Yang, L, Yang, YX, Ye, M, Ye, MH, Yin, JH, Yu, BX, Yu, CX, Yu, JS, Yuan, CZ, Yuan, WL, Yuan, Y, Yuncu, A, Zafar, AA, Zallo, A, Zeng, Y, Zeng, Z, Zhang, BX, Zhang, BY, Zhang, C, Zhang, CC, Zhang, DH, Zhang, HH, Zhang, HY, Zhang, JJ, Zhang, JL, Zhang, JQ, Zhang, JW, Zhang, JY, Zhang, JZ, Zhang, K, Zhang, L, Zhang, XY, Zhang, Y, Zhang, YH, Zhang, YN, Zhang, YT, Zhang, ZH, Zhang, ZP, Zhang, ZY, Zhao, G, Zhao, JW, Zhao, JY, Zhao, JZ, Zhao, L, Zhao, MG, Zhao, Q, Zhao, QW, Zhao, SJ, Zhao, TC, Zhao, YB, Zhao, ZG, Zhemchugov, A, Zheng, B, Zheng, JP, Zheng, WJ, Zheng, YH, Zhong, B, Zhou, L, Zhou, X, Zhou, XK, Zhou, XR, Zhou, XY, Zhu, K, Zhu, KJ, Zhu, S, Zhu, SH, Zhu, XL, Zhu, YC, Zhu, YS, Zhu, ZA, Zhuang, J, Zotti, L, Zou, BS, Zou, JH, Collaboration, BESIII, İstanbul Arel Üniversitesi, and [Ablikim, M. -- Ai, X. C. -- An, F. F. -- Bai, J. Z. -- Cai, X. -- Cao, G. F. -- Chang, J. F. -- Chen, G. -- Chen, H. S. -- Chen, J. C. -- Chen, M. L. -- Chen, X. -- Chen, Y. B. -- Dai, H. L. -- Deng, Z. Y. -- Dong, J. -- Dong, L. Y. -- Dong, M. Y. -- Duan, P. F. -- Fang, J. -- Fang, S. S. -- Fang, Y. -- Fu, C. D. -- Gao, Q. -- Gong, W. X. -- Gu, M. H. -- Guan, Y. H. -- Guo, A. Q. -- Guo, Y. -- He, K. L. -- Heng, Y. K. -- Hou, Z. L. -- Hu, H. M. -- Hu, T. -- Hu, Y. -- Ji, Q. -- Ji, X. B. -- Ji, X. L. -- Jiang, X. S. -- Jin, D. P. -- Jin, S. -- Kang, X. L. -- Li, F. -- Li, G. -- Li, H. B. -- Li, J. C. -- Li, W. D. -- Li, W. G. -- Li, X. N. -- Liu, B. J. -- Liu, C. X. -- Liu, Fang -- Liu, H. H. -- Liu, H. M. -- Liu, J. -- Liu, J. Y. -- Liu, P. L. -- Liu, Z. A. -- Lou, X. C. -- Lu, J. G. -- Lu, Y. -- Lu, Y. P. -- Luo, X. L. -- Ma, H. L. -- Ma, Q. M. -- Ma, T. -- Ma, X. Y. -- Mao, Z. P. -- Min, J. -- Mo, X. H. -- Ning, Z. -- Niu, S. L. -- Niu, X. Y. -- Ouyang, Q. -- Ping, R. G. -- Prasad, V. -- Qian, S. -- Qin, X. S. -- Qin, Z. H. -- Qiu, J. F. -- Rong, G. -- Shen, X. Y. -- Sheng, H. Y. -- Song, W. M. -- Song, X. Y. -- Sun, G. X. -- Sun, S. S. -- Sun, Y. Z. -- Sun, Z. J. -- Tang, X. -- Wang, K. -- Wang, L. L. -- Wang, L. S. -- Wang, R. -- Wang, P. L. -- Wang, W. -- Wang, Y. F. -- Wang, Z. -- Wang, Z. G. -- Wang, Z. Y. -- Wen, S. P. -- Wu, L. H. -- Wu, Z. -- Xiao, D. -- Xie, Y. G. -- Xiu, Q. L. -- Xu, G. F. -- Xu, L. -- Yang, H. X. -- Ye, M. -- Yin, J. H. -- Yu, B. X. -- Yuan, C. Z. -- Yuan, Y. -- Zhang, B. X. -- Zhang, B. Y. -- Zhang, C. C. -- Zhang, D. H. -- Zhang, H. Y. -- Zhang, J. J. -- Zhang, J. L. -- Zhang, J. Q. -- Zhang, J. W. -- Zhang, J. Y. -- Zhang, J. Z. -- Zhang, K. -- Zhang, L. -- Zhang, Y. -- Zhang, Y. H. -- Zhao, G. -- Zhao, J. W. -- Zhao, J. Y. -- Zhao, J. Z. -- Zhao, Ling -- Zhao, Q. -- Zhao, Q. W. -- Zhao, T. C. -- Zhao, Y. B. -- Zheng, J. P. -- Zhou, L. -- Zhou, X. Y. -- Zhu, K. -- Zhu, K. J. -- Zhu, S. -- Zhu, Y. S. -- Zhu, Z. A. -- Zhuang, J. -- Zou, B. S. -- Zou, J. H.] Inst High Energy Phys, Beijing 100049, Peoples R China -- [Chen, H. Y. -- Gao, X. Y. -- Qi, H. R. -- Shen, C. P.] Beihang Univ, Beijing 100191, Peoples R China -- [Li, Lei] Beijing Inst Petrochem Technol, Beijing 102617, Peoples R China -- [Albrecht, M. -- Held, T. -- Kopf, B. -- Pelizaeus, M. -- Wiedner, U.] Ruhr Univ Bochum, D-44780 Bochum, Germany -- [Albayrak, O. -- Bennett, J. V. -- Briere, R. A. -- Ke, B. C.] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA -- [Liu, Feng -- Mo, Y. J. -- Zhang, Z. H.] Cent China Normal Univ, Wuhan 430079, Peoples R China -- [Ye, M. H.] China Ctr Adv Sci & Technol, Beijing 100190, Peoples R China -- [Nisar, S.] COMSATS Inst Informat Technol, Def Rd,Off Raiwind Rd, Lahore 54000, Pakistan -- [Achasov, M. N. -- Muchnoi, N. Yu. -- Nikolaev, I. B.] GI Budker Inst Nucl Phys SB RAS BINP, Novosibirsk 630090, Russia -- [Goetzen, K. -- Peters, K.] GSI Helmholtzctr Heavy Ion Res GmbH, D-64291 Darmstadt, Germany -- [Liao, G. R. -- Wei, D. H. -- Yang, Y. X.] Guangxi Normal Univ, Guilin 541004, Peoples R China -- [Li, X. M. -- Liu, H. B. -- Ruan, X. D. -- Xia, Y.] Guangxi Univ, Nanning 530004, Peoples R China -- [Li, K. -- Xu, Q. J.] Hangzhou Normal Univ, Hangzhou 310036, Zhejiang, Peoples R China -- [Dbeyssi, A. -- Fritsch, M. -- Kliemt, R. -- Larin, R. -- Lin, D. X. -- Morales, C. Morales -- Nerling, F. -- Rosner, Ch. -- Wang, Y. D.] Helmholtz Inst Mainz, Johann Joachim Becher Weg 45, D-55099 Mainz, Germany -- [Hao, X. Q. -- Huang, J. S. -- Sun, J. F.] Henan Normal Univ, Xinxiang 453007, Peoples R China -- [Liu, H. H.] Henan Univ Sci & Technol, Luoyang 471003, Peoples R China -- [Cheng, H. P. -- Jiao, Z. -- Lu, H. J.] Huangshan Coll, Huangshan 245000, Peoples R China -- [Yan, Y. H. -- Zeng, Y.] Hunan Univ, Changsha 410082, Hunan, Peoples R China -- [Bennett, D. W. -- Lara, M. -- Mitchell, R. E. -- Sun, Z. T.] Indiana Univ, Bloomington, IN 47405 USA -- [Ferroli, R. Baldini -- Bertani, M. -- Calcaterra, A. -- Felici, G. -- Patteri, R. -- Zallo, A.] Ist Nazl Fis Nucl, Lab Nazl Frascati, I-00044 Frascati, Italy -- [Pacetti, S.] INFN, I-06100 Perugia, Italy -- [Pacetti, S.] Univ Perugia, I-06100 Perugia, Italy -- [Bettoni, D. -- Cibinetto, G. -- Farinelli, R. -- Fioravanti, E. -- Garzia, I. -- Santoro, V.] INFN, Sez Ferrara, I-44122 Ferrara, Italy -- [Farinelli, R. -- Savrie, M.] Univ Ferrara, I-44122 Ferrara, Italy -- [Denig, A. -- Feldbauer, F. -- Fritsch, M. -- Gradl, W. -- Guo, Y. P. -- Hafner, A. -- Kiese, R. -- Kloss, B. -- Liu, Zhiqing -- Redmer, C. F. -- Ripka, M. -- Schumann, S. -- Ullrich, M. -- Wang, Y. Q. -- Weber, T. -- Weidenkaff, R.] Johannes Gutenberg Univ Mainz, Johann Joachim Becher Weg 45, D-55099 Mainz, Germany -- [Boger, E. -- Boyko, I. -- Chelkov, G. -- Dedovich, D. -- Denysenko, I. -- Fedorov, O. -- Nefedov, Y. -- Sarantsev, A. -- Zhemchugov, A.] Joint Inst Nucl Res, Dubna 141980, Moscow Region, Russia -- [Kuehn, W. -- Lange, J. S. -- Liang, Y. T.] Univ Giessen, Inst Phys 2, Heinrich Buff Ring 16, D-35392 Giessen, Germany -- [Haddadi, Z. -- Kalantar-Nayestanaki, N. -- Kavatsyuk, M. -- Loehner, H. -- Messchendorp, J. G. -- Tiemens, M.] Univ Groningen, KVI CART, NL-9747 AA Groningen, Netherlands -- [Chen, X. R. -- Liu, X.] Lanzhou Univ, Lanzhou 730000, Peoples R China -- [Ding, Y. -- Liu, K. Y. -- Ma, F. C.] Liaoning Univ, Shenyang 110036, Peoples R China -- [Guo, L. B. -- Hu, C. -- Luo, C. L. -- Ping, J. L. -- Xiao, Z. J. -- Zhong, B.] Nanjing Normal Univ, Nanjing 210023, Jiangsu, Peoples R China -- [Chen, S. J. -- Dou, Z. L. -- Huang, Y. -- Qi, M. -- Yuan, W. L. -- Zhang, C.] Nanjing Univ, Nanjing 210093, Jiangsu, Peoples R China -- [Dong, C. -- Gong, L. -- Ji, Q. P. -- Jiang, X. Y. -- Kang, X. S. -- Li, X. Q. -- Liu, Y. B. -- Ma, X. N. -- Shen, P. X. -- Wang, B. -- Yu, C. X. -- Zhao, M. G.] Nankai Univ, Tianjin 300071, Peoples R China -- [Ban, Y. -- Chu, X. K. -- Li, F. Y. -- Liu, L. D. -- Mao, Y. J. -- Shan, W. -- Wang, D. -- Wang, D. Y. -- Wang, S. G. -- Wei, J. B.] Peking Univ, Beijing 100871, Peoples R China -- [Li, Jin -- Olsen, S. L.] Seoul Natl Univ, Seoul 151747, South Korea -- [Huang, X. T. -- Jiao, J. B. -- Li, K. -- Li, Q. Y. -- Li, T. -- Li, X. L. -- Ma, L. L. -- Ma, Y. M. -- Wang, M. -- Zhang, X. Y. -- Zheng, W. J.] Shandong Univ, Jinan 250100, Peoples R China -- [Dai, J. P. -- Yang, H. J.] Shanghai Jiao Tong Univ, Shanghai 200240, Peoples R China -- [Liu, F. H.] Shanxi Univ, Taiyuan 030006, Peoples R China -- [Liang, Y. F. -- Qin, L. Q. -- Tang, C. J.] Sichuan Univ, Chengdu 610064, Peoples R China -- [Xu, X. P.] Soochow Univ, Suzhou 215006, Peoples R China -- [Li, Z. B. -- Zhang, H. H.] Sun Yat Sen Univ, Guangzhou 510275, Guangdong, Peoples R China -- [Fan, J. Z. -- Gao, Y. -- Liu, K. -- Wang, X. F. -- Xia, L. G. -- Zhu, X. L.] Tsinghua Univ, Beijing 100084, Peoples R China -- [Cakir, O.] Istanbul Aydin Univ, TR-34295 Istanbul, Turkey -- [Cetin, S. A. -- Eren, E. E. -- Kolcu, O. B. -- Yuncu, A.] Istanbul Bilgi Univ, TR-34060 Istanbul, Turkey -- [Dong, C. -- Gong, L. -- Ji, Q. P. -- Jiang, X. Y. -- Kang, X. S. -- Li, X. Q. -- Liu, Y. B. -- Ma, X. N. -- Shen, P. X. -- Wang, B. -- Yu, C. X. -- Zhao, M. G.] Uludag Univ, TR-16059 Bursa, Turkey -- [Uman, I.] Near East Univ, TR-10 North Cyprus, Mersin, Turkey -- [Li, P. R. -- Liu, Q. -- Lyu, X. R. -- Qiao, C. F. -- Wang, B. L. -- Xu, Q. N. -- Zhang, Y. N. -- Zhang, Yu -- Zheng, Y. H.] Univ Chinese Acad Sci, Beijing 100049, Peoples R China -- [Harris, F. A. -- Kornicer, M. -- Luo, T. -- Varner, G. S.] Univ Hawaii, Honolulu, HI 96822 USA -- [Bian, J. M. -- Julin, A. -- Muramatsu, H. -- Poling, R.] Univ Minnesota, Minneapolis, MN 55455 USA -- [Ambrose, D. J. -- Thorndike, E. H.] Univ Rochester, Rochester, NY 14627 USA -- [Zhu, S. H.] Univ Sci & Technol Liaoning, Anshan 114051, Peoples R China -- [An, Q. -- Fang, X. -- Feng, C. Q. -- Gao, X. L. -- Gao, Z. -- Huang, G. S. -- Li, Cheng -- Liang, H. -- Liu, D. -- Liu, J. B. -- Liu, S. B. -- Pan, Y. -- Peng, H. P. -- Shao, M. -- Sun, Y. J. -- Wang, W. P. -- Wang, Z. H. -- Xia, L. -- Yan, W. B. -- Yan, W. C. -- Zeng, Z. -- Zhang, Y. T. -- Zhang, Z. P. -- Zhao, Lei -- Zhao, Z. G. -- Zhou, X. K. -- Zhou, X. R. -- Zhu, Y. C.] Univ Sci & Technol China, Hefei 230026, Peoples R China -- [Xiao, H. -- Zheng, B.] Univ South China, Hengyang 421001, Peoples R China -- [Hussain, T. -- Rashid, K. H. -- Zafar, A. A.] Univ Punjab, Lahore 54590, Pakistan -- [Amoroso, A. -- Bianchi, E. -- Destefanis, M. -- De Mori, F. -- Greco, M. -- Hu, J. F. -- Maggiura, M. -- Marcello, S. -- Sosio, S. -- Spataro, S. -- Yan, L. -- Zotti, L.] Univ Turin, I-10125 Turin, Italy -- [Fava, L. -- Johansson, T.] Univ Piemonte Orientale, I-15121 Alessandria, Italy -- [Amoroso, A. -- Bianchi, E. -- Destefanis, M. -- De Mori, F. -- Fava, L. -- Greco, M. -- Hu, J. F. -- Leng, C. -- Maggiura, M. -- Marcello, S. -- Sosio, S. -- Spataro, S. -- Yan, L. -- Zotti, L.] INFN, I-10125 Turin, Italy -- [Kupsc, A. -- Li, C. -- Pettersson, J. -- Schoenning, K. -- Wolke, M.] Uppsala Univ, Box 516, SE-75120 Uppsala, Sweden -- [Cai, H. -- Han, S. -- Jiang, L. W. -- Liu, J. P. -- Qin, N. -- Yang, L. -- Zhang, Z. Y. -- Zhou, X.] Wuhan Univ, Wuhan 430072, Peoples R China -- [Luo, M. X.] Zhejiang Univ, Hangzhou 310027, Zhejiang, Peoples R China -- [Du, S. X. -- Li, D. M. -- Zhao, S. J.] Zhengzhou Univ, Zhengzhou 450001, Peoples R China -- [An, Q. -- Cai, X. -- Chang, J. F. -- Chen, Y. B. -- Dai, H. L. -- Fang, X. -- Feng, C. Q. -- Gao, X. L. -- Gao, Z. -- Gong, W. X. -- Gu, Y. T. -- Heng, Y. K. -- Hu, T. -- Huang, G. S. -- Ji, X. L. -- Jiang, X. S. -- Jin, D. P. -- Lange, J. S. -- Li, F. -- Li, X. N. -- Liang, H. -- Liu, D. -- Liu, P. L. -- Liu, S. B. -- Liu, Z. A. -- Lou, X. C. -- Lu, J. G. -- Luo, X. L. -- Min, J. -- Mo, X. H. -- Ning, Z. -- Niu, S. L. -- Ouyang, Q. -- Pan, Y. -- Peng, H. P. -- Prasad, V. -- Shao, M. -- Sun, Y. J. -- Sun, Z. J. -- Wang, K. -- Wang, W. -- Wang, W. P. -- Wang, Y. F. -- Wang, Z. -- Wang, Z. G. -- Wang, Z. H. -- Wu, Z. -- Xia, L. -- Xie, Y. G. -- Xiu, Q. L. -- Yan, W. B. -- Yan, W. C. -- Ye, M. -- Yu, B. X. -- Zeng, Z. -- Zhang, B. Y. -- Zhang, H. Y. -- Zhang, J. W. -- Zhang, Y. H. -- Zhang, Y. T. -- Zhao, J. W. -- Zhao, J. Z. -- Zhao, Lei -- Zhao, Y. B. -- Zhao, Z. G. -- Zhou, L. -- Zhou, X. K. -- Zhou, X. R. -- Zhu, K. J. -- Zhu, Y. C. -- Zhuang, J.] State Key Lab Particle Detect & Elect, Beijing 100049, Peoples R China -- [Cakir, O.] Ankara Univ, TR-06100 Ankara, Turkey -- [Yuncu, A.] Bogazici Univ, TR-34342 Istanbul, Turkey -- [Boger, E. -- Chelkov, G. -- Zhemchugov, A.] Moscow Inst Phys & Technol, Moscow 141700, Russia -- [Chelkov, G.] Tomsk State Univ, Funct Elect Lab, Tomsk 634050, Russia -- [Muchnoi, N. Yu. -- Nikolaev, I. B.] Novosibirsk State Univ, Novosibirsk 630090, Russia -- [Sarantsev, A.] NRC Kurchatov Inst, PNPI, Gatchina 188300, Russia -- [Lou, X. C.] Univ Texas Dallas, Richardson, TX 75083 USA -- [Kolcu, O. B.] Istanbul Arel Univ, TR-34295 Istanbul, Turkey
- Abstract
WOS: 000368783600015, By analyzing a data set of 2.92 fb(-1) of e(+) e(-) collision data taken at root s = 3.773 GeVand 106.41 x 10(6) psi(3686) decays taken at root s = 3.686 GeVwith the BESIII detector at the BEPCII collider, we measure the branching fraction and the partial decay width for psi(3770)->gamma chi c0 to be B(psi(3770)->gamma chi c0) = (6.88 +/- 0.28 +/- 0.67) x 10(-3) and Gamma[psi(3770)->gamma chi c0] = (187 +/- 8 +/- 19) keV, respectively. These are the most precise measurements to date. (C) 2015 The Authors. Published by Elsevier B.V., National Key Basic Research Program of China [2009CB825204, 2015CB856700]; National Natural Science Foundation of China (NSFC) [10935007, 11125525, 11235011, 11305180, 11322544, 11335008, 11425524]; Chinese Academy of Sciences (CAS) Large-Scale Scientific Facility Program; NSFC [11179007, U1232201, U1332201]; CAS [11179007, U1232201, U1332201, KJCX2-YW-N29, KJCX2-YW-N45]; 100 Talents Program of CAS; CAS Center for Excellence in Particle Physics (CCEPP); INPAC; Shanghai Key Laboratory for Particle Physics and Cosmology; German Research Foundation DFG under Collaborative Research Center [CRC-1044]; Istituto Nazionale di Fisica Nucleare, Italy; Ministry of Development of Turkey [DPT2006K-120470]; Russian Foundation for Basic Research [14-07-91152]; U.S. Department of Energy [DE-FG02-04ER41291, DE-FG02-05ER41374, DE-FG02-94ER40823, DESC0010118]; U.S. National Science Foundation; University of Groningen (RuG); Helmholtzzentrum fur Schwerionenforschung GmbH (GSI), Darmstadt; WCU Program of National Research Foundation of Korea [R32-2008-000-10155-0], The BESIII collaboration thanks the staff of BEPCII and the IHEP computing center for their strong support. This work is supported in part by the National Key Basic Research Program of China under Contract Nos. 2009CB825204 and 2015CB856700; National Natural Science Foundation of China (NSFC) under Contracts Nos. 10935007, 11125525, 11235011, 11305180, 11322544, 11335008, 11425524; the Chinese Academy of Sciences (CAS) Large-Scale Scientific Facility Program; Joint Large-Scale Scientific Facility Funds of the NSFC and CAS under Contracts Nos. 11179007, U1232201, U1332201; CAS under Contracts Nos. KJCX2-YW-N29, KJCX2-YW-N45; 100 Talents Program of CAS; the CAS Center for Excellence in Particle Physics (CCEPP); INPAC and Shanghai Key Laboratory for Particle Physics and Cosmology; German Research Foundation DFG under Collaborative Research Center Contract No. CRC-1044; Istituto Nazionale di Fisica Nucleare, Italy; Ministry of Development of Turkey under Contract No. DPT2006K-120470; Russian Foundation for Basic Research under Contract No. 14-07-91152; U.S. Department of Energy under Contracts Nos. DE-FG02-04ER41291, DE-FG02-05ER41374, DE-FG02-94ER40823, DESC0010118; U.S. National Science Foundation; University of Groningen (RuG) and the Helmholtzzentrum fur Schwerionenforschung GmbH (GSI), Darmstadt; WCU Program of National Research Foundation of Korea under Contract No. R32-2008-000-10155-0.
- Published
- 2016
- Full Text
- View/download PDF
28. Culte des martyrs et reliquaires : les paradoxes de l'Afrique
- Author
-
Baratte, François, Baratte, François, and E. Destefanis
- Subjects
[SHS.ARCHEO] Humanities and Social Sciences/Archaeology and Prehistory ,Afrique romaine et byzantine ,culte des martyrs ,reliquaire ,église ,[SHS.ART] Humanities and Social Sciences/Art and art history ,[SHS.RELIG] Humanities and Social Sciences/Religions - Published
- 2022
29. De Novo Bladder Urothelial Neoplasm in Renal Transplant Recipients: A Retrospective, Multicentered Study
- Author
-
Andrea Bosio, Antonia Di Domenico, Carlo Terrone, Paola Todeschini, Samuele Iesari, Fabrizio Fop, Antonio Famulari, Ettore Dalmasso, Giuseppe Paolo Segoloni, Anna Palazzetti, Paolo Gontero, Paolo Destefanis, Bruno Frea, Alessandro Volpe, Luigi Biancone, Francesca Pisano, and Palazzetti A, Bosio A, Dalmasso E, Destefanis P, Fop F, Pisano F, Segoloni G, Biancone L, Volpe A, Di Domenico A, Terrone C, Iesari S, Famulari A, Todeschini P, Frea B, Gontero P.
- Subjects
Male ,Time Factors ,medicine.medical_treatment ,030232 urology & nephrology ,Urothelial neoplasm ,Kaplan-Meier Estimate ,Kidney ,0302 clinical medicine ,Risk Factors ,Neoplasm ,education.field_of_study ,Incidence (epidemiology) ,Bladder cancer ,Immunosuppression ,Middle Aged ,Treatment Outcome ,medicine.anatomical_structure ,Renal transplant ,Italy ,030220 oncology & carcinogenesis ,Cohort ,Disease Progression ,Female ,Adult ,medicine.medical_specialty ,Urology ,Population ,Disease-Free Survival ,Cystectomy ,Young Adult ,03 medical and health sciences ,medicine ,Humans ,education ,Aged ,Retrospective Studies ,Carcinoma, Transitional Cell ,business.industry ,medicine.disease ,Kidney Transplantation ,Transplant Recipients ,Urinary Bladder Neoplasms ,Neoplasm Recurrence, Local ,Urothelium ,business - Abstract
Background and Objectives: Renal transplant recipients (RTRs) have a 2- to 7-fold risk of developing a neoplasm compared to general population. Bladder urothelial neoplasms in this cohort has an incidence of 0.4–2%. Many reports describe a more aggressive behavior. The objective of this study is to describe oncologic characteristics of bladder urothelial neoplasms in RTRs and to evaluate its recurrence, progression, and survival rates. Methods: A retrospective multicentered study was performed evaluating all de novo bladder urothelial neoplasms cases in RTRs from 1988 to 2014. Descriptive statistical analysis and evaluation of recurrence, progression, and survival rates were performed. Results: A total of 28 de novo bladder transitional cell carcinomas (TCCs) were identified (incidence rate 0.64%). Cancer-specific survival rates were 100, 75, and 70% after 1, 5, and 10 years, respectively. Age at diagnosis superior to 60 years was found to be a statistically significant variable for recurrence risk. Progression rate was 14%. Presence of CIS was significantly associated with progression. All cancer-specific deaths were in the high-risk group and all were progressions from non-muscle invasive to muscle invasive bladder cancer. Conclusions: Bladder urothelial neoplasms following renal transplant is associated with a trend toward worst prognosis. Early aggressive treatments, such as early radical cystectomy, might be advisable to reduce cancer-specific deaths.
- Published
- 2018
30. The three YTHDF paralogs and VIRMA are strong cross-histotype tumor driver candidates among m 6 A core genes.
- Author
-
Destefanis E, Sighel D, Dalfovo D, Gilmozzi R, Broso F, Cappannini A, Bujnicki JM, Romanel A, Dassi E, and Quattrone A
- Abstract
N
6 -Methyladenosine (m6 A) is the most abundant internal modification in mRNAs. Despite accumulating evidence for the profound impact of m6 A on cancer biology, there are conflicting reports that alterations in genes encoding the m6 A machinery proteins can either promote or suppress cancer, even in the same tumor type. Using data from The Cancer Genome Atlas, we performed a pan-cancer investigation of 15 m6 A core factors in nearly 10000 samples from 31 tumor types to reveal underlying cross-tumor patterns. Altered expression, largely driven by copy number variations at the chromosome arm level, results in the most common mode of dysregulation of these factors. YTHDF1, YTHDF2, YTHDF3 and VIRMA are the most frequently altered factors and the only ones to be uniquely altered when tumors are grouped according to the expression pattern of the m6 A factors. These genes are also the only ones with coherent, pan-cancer predictive power for progression-free survival. On the contrary, METTL3, the most intensively studied m6 A factor as a cancer target, shows much lower levels of alteration and no predictive power for patient survival. Therefore, we propose the non-enzymatic YTHDF and VIRMA genes as preferred subjects to dissect the role of m6 A in cancer and as priority cancer targets., (© The Author(s) 2024. Published by Oxford University Press on behalf of NAR Cancer.)- Published
- 2024
- Full Text
- View/download PDF
31. Therapeutic strategies to target the epitranscriptomic machinery.
- Author
-
Sighel D, Destefanis E, and Quattrone A
- Subjects
- Humans, Transcriptome genetics, RNA Processing, Post-Transcriptional genetics, RNA genetics, RNA metabolism, Adenosine analogs & derivatives, Adenosine metabolism, Adenosine genetics, Methyltransferases genetics, Methyltransferases metabolism, Animals, Epigenesis, Genetic
- Abstract
Altered RNA modification patterns and dysregulated expression of epitranscriptomic machinery proteins (EMPs) have been causatively correlated with several diseases. Modulation of EMP gene expression has shown promise in reversing disease-associated phenotypes, making EMPs attractive therapeutic targets. Various therapeutic strategies, including small-molecule modulators, proteolysis-targeting chimeras, and molecular tools for site-specific engineering of RNA modifications, have been introduced to modulate EMPs and RNA modifications themselves and are currently being investigated to enrich the physician's armamentarium. At the forefront of research are small-molecule inhibitors of the key players involved in the N
6 -methyladenosine RNA modification, with an inhibitor of methyltransferase 3 in clinical trials. Preclinical studies have also demonstrated proof-of-concept for the other approaches, raising expectations for this exciting new frontier of therapy., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
32. Elongated styloid process of an autopsied skull from the Cemetery of Santa Maria Maggiore in Vercelli, 18 th -19 th century (Piedmont, northern Italy).
- Author
-
Licata M, Tesi C, Larentis O, Destefanis E, Garanzini F, Ciliberti R, and Fusco R
- Subjects
- Male, Adult, Humans, Temporal Bone pathology, Temporal Bone surgery, Autopsy, Cemeteries, Temporal Bone abnormalities, Ossification, Heterotopic pathology, Ossification, Heterotopic surgery
- Abstract
We discuss the coexistence of a postmortem cut and a pathological alteration, recorded on a skeleton belonging to an adult man that was discovered during the archaeological investigations of the cemetery of the Church of Santa Maria Maggiore in Vercelli (northern Italy, 18
th -19th century). The skull presents an oblique cleft, which from the top of the frontal bone bends towards the occipital, and the left styloid process is elongated compared to normal values (48 mm). The elongated styloid process is due to the ossification of the styloid ligament which has several possible causes. To increase the knowledge about this pathological condition in the past, it was necessary to compare all the data present in the literature today and consider the few cases published in the paleopathological field. In this paper, our main goals are: i) to investigate the reasons for which the craniotomy was performed; ii) to examine the possible cause of the ossification of the styloid process, described as Eagle's syndrome; iii) to enrich the archaeological literature of elongated styloid process cases and iv) to investigate the presence of a hypothetical relationship between the autopsy cut and the diagnosed Eagle's syndrome on this skull.- Published
- 2024
- Full Text
- View/download PDF
33. Alpha-1 Adrenergic Antagonists Sensitize Neuroblastoma to Therapeutic Differentiation.
- Author
-
Broso F, Gatto P, Sidarovich V, Ambrosini C, De Sanctis V, Bertorelli R, Zaccheroni E, Ricci B, Destefanis E, Longhi S, Sebastiani E, Tebaldi T, Adami V, and Quattrone A
- Subjects
- Humans, Mice, Child, Animals, Adrenergic alpha-1 Receptor Antagonists therapeutic use, Cell Line, Tumor, Neoplasm Recurrence, Local, Cell Differentiation, Receptors, Adrenergic therapeutic use, Recurrence, N-Myc Proto-Oncogene Protein, Isotretinoin pharmacology, Isotretinoin therapeutic use, Neuroblastoma drug therapy, Neuroblastoma genetics, Neuroblastoma metabolism
- Abstract
Neuroblastoma (NB) is an aggressive childhood tumor, with high-risk cases having a 5-year overall survival probability of approximately 50%. The multimodal therapeutic approach for NB includes treatment with the retinoid isotretinoin (13-cis retinoic acid; 13cRA), which is used in the post-consolidation phase as an antiproliferation and prodifferentiation agent to minimize residual disease and prevent relapse. Through small-molecule screening, we identified isorhamnetin (ISR) as a synergistic compound with 13cRA in inhibiting up to 80% of NB cell viability. The synergistic effect was accompanied by a marked increase in the expression of the adrenergic receptor α1B (ADRA1B) gene. Genetic knockout of ADRA1B or its specific blockade using α1/α1B adrenergic antagonists led to selective sensitization of MYCN-amplified NB cells to cell viability reduction and neural differentiation induced by 13cRA, thus mimicking ISR activity. Administration of doxazosin, a safe α1-antagonist used in pediatric patients, in combination with 13cRA in NB xenografted mice exerted marked control of tumor growth, whereas each drug alone was ineffective. Overall, this study identified the α1B adrenergic receptor as a pharmacologic target in NB, supporting the evaluation of adding α1-antagonists to the post-consolidation therapy of NB to more efficiently control residual disease., Significance: Targeting α-adrenergic receptors synergizes with isotretinoin to suppress growth and to promote differentiation of neuroblastoma, revealing a combinatorial approach for more effective management of the disease and prevention of relapse., (©2023 American Association for Cancer Research.)
- Published
- 2023
- Full Text
- View/download PDF
34. QUADRatlas: the RNA G-quadruplex and RG4-binding proteins database.
- Author
-
Bourdon S, Herviou P, Dumas L, Destefanis E, Zen A, Cammas A, Millevoi S, and Dassi E
- Subjects
- Humans, Carrier Proteins metabolism, RNA-Binding Proteins genetics, RNA-Binding Proteins metabolism, Transcriptome, Atlases as Topic, G-Quadruplexes, RNA genetics, RNA chemistry
- Abstract
RNA G-quadruplexes (RG4s) are non-canonical, disease-associated post-transcriptional regulators of gene expression whose functions are driven by RNA-binding proteins (RBPs). Being able to explore transcriptome-wide RG4 formation and interaction with RBPs is thus paramount to understanding how they are regulated and exploiting them as potential therapeutic targets. Towards this goal, we present QUADRatlas (https://rg4db.cibio.unitn.it), a database of experimentally-derived and computationally predicted RG4s in the human transcriptome, enriched with biological function and disease associations. As RBPs are key to their function, we mined known interactions of RG4s with such proteins, complemented with an extensive RBP binding sites dataset. Users can thus intersect RG4s with their potential regulators and effectors, enabling the formulation of novel hypotheses on RG4 regulation, function and pathogenicity. To support this capability, we provide analysis tools for predicting whether an RBP can bind RG4s, RG4 enrichment in a gene set, and de novo RG4 prediction. Genome-browser and table views allow exploring, filtering, and downloading the data quickly for individual genes and in batch. QUADRatlas is a significant step forward in our ability to understand the biology of RG4s, offering unmatched data content and enabling the integrated analysis of RG4s and their interactions with RBPs., (© The Author(s) 2022. Published by Oxford University Press on behalf of Nucleic Acids Research.)
- Published
- 2023
- Full Text
- View/download PDF
35. Translational enhancement by base editing of the Kozak sequence rescues haploinsufficiency.
- Author
-
Ambrosini C, Destefanis E, Kheir E, Broso F, Alessandrini F, Longhi S, Battisti N, Pesce I, Dassi E, Petris G, Cereseto A, and Quattrone A
- Subjects
- Alleles, Codon, Initiator, Humans, RNA, Messenger metabolism, Haploinsufficiency genetics, Nucleotides
- Abstract
A variety of single-gene human diseases are caused by haploinsufficiency, a genetic condition by which mutational inactivation of one allele leads to reduced protein levels and functional impairment. Translational enhancement of the spare allele could exert a therapeutic effect. Here we developed BOOST, a novel gene-editing approach to rescue haploinsufficiency loci by the change of specific single nucleotides in the Kozak sequence, which controls translation by regulating start codon recognition. We evaluated for translational strength 230 Kozak sequences of annotated human haploinsufficient genes and 4621 derived variants, which can be installed by base editing, by a high-throughput reporter assay. Of these variants, 149 increased the translation of 47 Kozak sequences, demonstrating that a substantial proportion of haploinsufficient genes are controlled by suboptimal Kozak sequences. Validation of 18 variants for 8 genes produced an average enhancement in an expression window compatible with the rescue of the genetic imbalance. Base editing of the NCF1 gene, whose monoallelic loss causes chronic granulomatous disease, resulted in the desired increase of NCF1 (p47phox) protein levels in a relevant cell model. We propose BOOST as a fine-tuned approach to modulate translation, applicable to the correction of dozens of haploinsufficient monogenic disorders independently of the causing mutation., (© The Author(s) 2022. Published by Oxford University Press on behalf of Nucleic Acids Research.)
- Published
- 2022
- Full Text
- View/download PDF
36. Influence of speciation distribution and particle size on heavy metal leaching from MSWI fly ash.
- Author
-
Bernasconi D, Caviglia C, Destefanis E, Agostino A, Boero R, Marinoni N, Bonadiman C, and Pavese A
- Subjects
- Carbon, Coal Ash, Incineration, Particle Size, Particulate Matter, Solid Waste, Metals, Heavy analysis, Refuse Disposal
- Abstract
Fly ash from municipal solid waste incineration (MSWI-FA) contains leachable heavy metals. In the present study the correlations between heavy metal content, particle size, speciation distribution with respect to water leaching are investigated, using a combination of solid-state bulk analytical techniques, leaching treatments, sequential extractions and thermodynamic geochemical modelling. Among the analyzed heavy metals, Zn and Pb are the most abundant in any grain size class, followed by Cu, Cr, Cd and Ni, with concentration that tends to increase with a decrease of the grain size. The phase composition is constituted of salt (halite, sylvite, anhydrite and syngenite), which provide the main minerals regardless of the particle size class; calcite, quartz and gehlenite occur in comparatively lower amounts, while 50% wt is composed of amorphous fraction. Heavy metal leaching is strongly correlated to speciation distribution, and in particular to the fraction (F1) associated with salt, carbonate and weak surface sorption. Leaching from speciation due to surface complexation on Al/Fe (hydr)oxide becomes relevant at acidic regime. Particle size and heavy metal content, in turn, moderately correlate with leaching. The F1-speciation as a function of particle size does not exhibit a definite trend shared by all heavy metals under investigation. This suggests that i) differences in speciation distribution, rather than bare heavy metal content or particle size, govern leaching from MSWI-FA; ii) F1 can be regarded as a marker of the potential heavy metal leaching; iii) a comparatively modest efficiency in managing MSWI-FA is expected from grain size separation strategies., (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
37. MODOMICS: a database of RNA modification pathways. 2021 update.
- Author
-
Boccaletto P, Stefaniak F, Ray A, Cappannini A, Mukherjee S, Purta E, Kurkowska M, Shirvanizadeh N, Destefanis E, Groza P, Avşar G, Romitelli A, Pir P, Dassi E, Conticello SG, Aguilo F, and Bujnicki JM
- Subjects
- Base Sequence, Cardiovascular Diseases genetics, Cardiovascular Diseases metabolism, Cardiovascular Diseases pathology, Computer Graphics, Databases, Protein, Datasets as Topic, Enzymes metabolism, Gastrointestinal Diseases genetics, Gastrointestinal Diseases metabolism, Gastrointestinal Diseases pathology, Hematologic Diseases genetics, Hematologic Diseases metabolism, Hematologic Diseases pathology, Humans, Internet, Mental Disorders genetics, Mental Disorders metabolism, Mental Disorders pathology, Musculoskeletal Diseases genetics, Musculoskeletal Diseases metabolism, Musculoskeletal Diseases pathology, Mutation, Neoplasms genetics, Neoplasms metabolism, Neoplasms pathology, Neurodegenerative Diseases genetics, Neurodegenerative Diseases metabolism, Neurodegenerative Diseases pathology, RNA metabolism, RNA Processing, Post-Transcriptional, Ribonucleosides metabolism, Saccharomyces cerevisiae genetics, Saccharomyces cerevisiae metabolism, Databases, Nucleic Acid, Enzymes genetics, RNA genetics, Ribonucleosides genetics, User-Computer Interface
- Abstract
The MODOMICS database has been, since 2006, a manually curated and centralized resource, storing and distributing comprehensive information about modified ribonucleosides. Originally, it only contained data on the chemical structures of modified ribonucleosides, their biosynthetic pathways, the location of modified residues in RNA sequences, and RNA-modifying enzymes. Over the years, prompted by the accumulation of new knowledge and new types of data, it has been updated with new information and functionalities. In this new release, we have created a catalog of RNA modifications linked to human diseases, e.g., due to mutations in genes encoding modification enzymes. MODOMICS has been linked extensively to RCSB Protein Data Bank, and sequences of experimentally determined RNA structures with modified residues have been added. This expansion was accompanied by including nucleotide 5'-monophosphate residues. We redesigned the web interface and upgraded the database backend. In addition, a search engine for chemically similar modified residues has been included that can be queried by SMILES codes or by drawing chemical molecules. Finally, previously available datasets of modified residues, biosynthetic pathways, and RNA-modifying enzymes have been updated. Overall, we provide users with a new, enhanced, and restyled tool for research on RNA modification. MODOMICS is available at https://iimcb.genesilico.pl/modomics/., (© The Author(s) 2021. Published by Oxford University Press on behalf of Nucleic Acids Research.)
- Published
- 2022
- Full Text
- View/download PDF
38. Introduction to Bioinformatics Resources for Post-transcriptional Regulation of Gene Expression.
- Author
-
Destefanis E and Dassi E
- Subjects
- RNA, Messenger genetics, RNA, Untranslated, Transcription, Genetic, Untranslated Regions, Computational Biology, Gene Expression Regulation
- Abstract
Untranslated regions of mRNA (UTRs) are involved in defining the fate of the transcript through processes such as mRNA localization, degradation, translation initiation regulation, and several others: the action of trans-factors such as RNA-binding proteins and non-coding RNAs, combined with the presence of defined sequence and structural cis-elements, ultimately determines protein synthesis levels. Identifying functional regions in UTRs and uncovering post-transcriptional regulators acting upon these is thus of paramount importance to understand this regulatory layer: these tasks can now be approached computationally to reduce the testable hypothesis space and drive the experimental validation in a more effective way.This chapter will focus on presenting databases and tools allowing to study the various aspects of post-transcriptional regulation, including the profiling of actively translated mRNAs, regulatory network analysis (e.g., RBP and ncRNA binding sites), trans-factor binding sites prediction, motif search (sequence and secondary structure), and other aspects of this regulatory layer: two potential analysis pipelines are also presented as practical examples of how these tools could be integrated and effectively employed., (© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
39. A mark of disease: how mRNA modifications shape genetic and acquired pathologies.
- Author
-
Destefanis E, Avşar G, Groza P, Romitelli A, Torrini S, Pir P, Conticello SG, Aguilo F, and Dassi E
- Subjects
- Apoptosis genetics, Cell Cycle genetics, Epigenesis, Genetic, Genetic Markers, Humans, Metabolic Diseases metabolism, Metabolic Diseases pathology, Neoplasms metabolism, Neoplasms pathology, Nervous System Diseases metabolism, Nervous System Diseases pathology, RNA, Messenger metabolism, RNA, Untranslated metabolism, Metabolic Diseases genetics, Neoplasms genetics, Nervous System Diseases genetics, RNA Processing, Post-Transcriptional, RNA, Messenger genetics, RNA, Untranslated genetics
- Abstract
RNA modifications have recently emerged as a widespread and complex facet of gene expression regulation. Counting more than 170 distinct chemical modifications with far-reaching implications for RNA fate, they are collectively referred to as the epitranscriptome. These modifications can occur in all RNA species, including messenger RNAs (mRNAs) and noncoding RNAs (ncRNAs). In mRNAs the deposition, removal, and recognition of chemical marks by writers, erasers and readers influence their structure, localization, stability, and translation. In turn, this modulates key molecular and cellular processes such as RNA metabolism, cell cycle, apoptosis, and others. Unsurprisingly, given their relevance for cellular and organismal functions, alterations of epitranscriptomic marks have been observed in a broad range of human diseases, including cancer, neurological and metabolic disorders. Here, we will review the major types of mRNA modifications and editing processes in conjunction with the enzymes involved in their metabolism and describe their impact on human diseases. We present the current knowledge in an updated catalog. We will also discuss the emerging evidence on the crosstalk of epitranscriptomic marks and what this interplay could imply for the dynamics of mRNA modifications. Understanding how this complex regulatory layer can affect the course of human pathologies will ultimately lead to its exploitation toward novel epitranscriptomic therapeutic strategies., (© 2021 Destefanis et al.; Published by Cold Spring Harbor Laboratory Press for the RNA Society.)
- Published
- 2021
- Full Text
- View/download PDF
40. CO 2 capture and sequestration in stable Ca-oxalate, via Ca-ascorbate promoted green reaction.
- Author
-
Pastero L, Curetti N, Ortenzi MA, Schiavoni M, Destefanis E, and Pavese A
- Abstract
The increase in the amount of carbon dioxide (CO
2 ) emissions related to many anthropic activities is a persistent and growing problem. During the last years, many solutions have been set out, none of them being the ultimate one. Investigators agree on the need of a synergic approach to the problem, in terms of many complementary methods of sequestration that, combined with the reduction of production, will be able to decrease the concentration of the CO2 in the atmosphere. In this work, we explore the use of a green reaction to trap the CO2 into a stable crystalline phase (weddellite) resorting to a multidisciplinary approach. CO2 is reduced and precipitated as calcium oxalate through vitamin C as a sacrificial reductant. Calcium oxalate crystals obtained show a startling good quality that increases their already great stability over a wide chemical and physical conditions' range., (Copyright © 2019 Elsevier B.V. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
41. Effects of particle size on properties and thermal inertization of bottom ashes (MSW of Turin's incinerator).
- Author
-
Caviglia C, Confalonieri G, Corazzari I, Destefanis E, Mandrone G, Pastero L, Boero R, and Pavese A
- Subjects
- Cities, Incineration, Italy, Particle Size, Coal Ash, Metals, Heavy
- Abstract
The aim of this study is twofold: (i) characterization of the bottom ashes from the Incinerator plant of the city of Turin (northern Italy), in terms of their chemical/phase compositions and capacity to release heavy metals in leachates, as a function of particle size; (ii) investigation of thermal treatments' efficacy to promote inertization of the same bottom ashes, exploring time-temperature ranges with t ≤ 6 h and T ≤ 1000 °C. Special attention is paid to macro-sampling techniques in order to have samples that are representative of the average bottom ashes production. Micro-XRF, ICP-OES, SEM-EDS, Ion Chromatography and X-ray powder diffraction were used to investigate bottom ashes and leachates. Bottom ashes are mainly constituted by an amorphous phase, ∼66-97 wt%, regardless of particle size; the remaining phases are quartz, calcite, Fe-oxides, melilite and other minor crystalline materials. The amorphous phase exhibits a relevant dependence on particle size, and undergoes dissolution in water up to 20 wt%, thus being the most important component in affecting chemical species release. The smaller the bottom ashes' particle size, the more the heavy metals (major species: Zn, Cu, Ti, Pb) and calcium contents increase, whereas silicon's decreases. Electrolytic current observations in combination with phase/chemical composition and metals release as a function of particle size, suggest that bottom ashes partition into two classes, i.e. ≥1 and <1 mm, for inertization purposes. Thermal treatments exhibit partial efficacy to curb heavy metals mobility: whilst they reduce Cu release, they lead to a inverse effect in the case of Cr., (Copyright © 2018 Elsevier Ltd. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
42. sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tumour resistance in combination with Bortezomib.
- Author
-
Loi M, Becherini P, Emionite L, Giacomini A, Cossu I, Destefanis E, Brignole C, Di Paolo D, Piaggio F, Perri P, Cilli M, Pastorino F, and Ponzoni M
- Subjects
- Animals, Antineoplastic Agents pharmacokinetics, Antineoplastic Combined Chemotherapy Protocols, Apoptosis drug effects, Bortezomib, Cell Line, Tumor, Female, Humans, Liposomes, Mice, Mice, Nude, Neuroblastoma pathology, TNF-Related Apoptosis-Inducing Ligand pharmacokinetics, Antineoplastic Agents administration & dosage, Antineoplastic Agents therapeutic use, Boronic Acids administration & dosage, Boronic Acids therapeutic use, Neuroblastoma drug therapy, Pyrazines administration & dosage, Pyrazines therapeutic use, TNF-Related Apoptosis-Inducing Ligand administration & dosage, TNF-Related Apoptosis-Inducing Ligand therapeutic use
- Abstract
Neuroblastoma (NB), the most common and deadly extracranial solid tumour of childhood, represents a challenging in paediatric oncology. Soluble tumour necrosis factor (TNF)-related apoptosis-inducing ligand (sTRAIL) is a cancer cell-specific molecule exerting remarkable anti-tumour activities against paediatric malignancies both in vitro and in preclinical settings. However, due to its too fast elimination and to the undesired related side effects, the improvement of sTRAIL in vivo bioavailability and the specific delivery to the tumour is mandatory for increasing its therapeutic efficacy. In this manuscript, we developed an innovative pegylated liposomal formulation carrying the sTRAIL at the outer surface (sTRAIL-SL) with the intent to improve its serum half-life and increase its efficacy in vivo, while reducing side effects. Furthermore, the possibility to combine sTRAIL-SL with the proteasome inhibitor Bortezomib (BTZ) was investigated, being BTZ able to sensitize tumour cells toward TRAIL-induced apoptosis. We demonstrated that sTRAIL preserved and improved its anti-tumour activity when coupled to nanocarriers. Moreover, sTRAIL-SL ameliorated its PK profile in blood allowing sTRAIL to exert a more potent anti-tumour activity, which led, upon BTZ priming, to a statistically significant enhanced life spans in two models of sTRAIL-resistant NB-bearing mice. Finally, mechanistic studies indicated that the combination of sTRAIL with BTZ sensitized sTRAIL-resistant NB tumour cells to sTRAIL-induced cell death, both in vitro and in vivo, through the Akt/GSK3/β-catenin axis-dependent mechanism. In conclusion, our results suggest that sTRAIL-SL might be an efficient vehicle for sTRAIL delivery and that its use in clinic, in combination with BTZ, might represent an adjuvant strategy for the treatment of stage IV, sTRAIL-resistant, NB patients., (Copyright © 2014 Elsevier B.V. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
43. Gait and bilateral limb ataxia as isolated feature of a lower midbrain tegmental infarction. A clinical-MRI study.
- Author
-
Cerrato P, Lentini A, Colonna R, Bosco G, Destefanis E, Caprioli M, and Bergui M
- Subjects
- Aged, Coronary Thrombosis chemically induced, Coronary Thrombosis diagnostic imaging, Echocardiography, Transesophageal, Humans, Magnetic Resonance Imaging, Male, Neurologic Examination, Tomography, X-Ray Computed, Ataxia etiology, Cerebral Infarction complications, Cerebral Infarction pathology, Gait Disorders, Neurologic etiology, Tegmentum Mesencephali pathology
- Published
- 2008
- Full Text
- View/download PDF
44. Vertebral artery dissection complicated by basilar artery occlusion successfully treated with intra-arterial thrombolysis: three case reports.
- Author
-
Cerrato P, Berardino M, Bottacchi E, Corso G, Lentini A, Bosco G, Destefanis E, Caprioli M, Daniele D, Bradac GB, and Bergui M
- Subjects
- Adult, Brain Ischemia etiology, Cerebral Angiography, Cerebral Infarction etiology, Female, Humans, Injections, Intra-Arterial, Male, Middle Aged, Thromboembolism complications, Basilar Artery pathology, Thromboembolism drug therapy, Thrombolytic Therapy, Tissue Plasminogen Activator administration & dosage, Vertebral Artery Dissection complications, Vertebral Artery Dissection drug therapy
- Abstract
Cervical artery dissection is an important cause of stroke in young patients and accounts of 10%-20% of stroke or TIA in patients aged less than 50 years. Basilar artery occlusion (BAO) is an infrequent cause of acute stroke, which invariably leads to death or long-term disability if not recanalized. We describe three patients with BAO caused by vertebral dissection, successfully treated with intra-arterial thrombolysis. The lysis of the occluding embolus was obtained by injection of the thrombolytic drug directly or near the thrombus without haemorrhagic complications. Our cases confirm the safety and efficacy of intra-arterial thrombolysis in patients with BAO due to a vertebral artery dissection.
- Published
- 2008
- Full Text
- View/download PDF
45. Atherosclerotic adult Moya-Moya disease in a patient with hyperhomocysteinaemia.
- Author
-
Cerrato P, Grasso M, Lentini A, Destefanis E, Bosco G, Caprioli M, Bradac GB, and Bergui M
- Subjects
- Atherosclerosis diagnostic imaging, Humans, Magnetic Resonance Angiography methods, Male, Middle Aged, Radiography, Atherosclerosis complications, Hyperhomocysteinemia complications, Moyamoya Disease complications
- Abstract
Moya-Moya is a rare cerebrovascular occlusive disease characterized by bilateral stenosis or occlusion at the terminal portion of the internal carotid artery and abnormal vascular network at the base of the brain, named "moya-moya". In children, Moya-Moya disease usually presents with ischemic cerebrovascular events, mainly TIA or lacunar stroke, leading to mental deterioration. In adults, especially in females, it presents with intracranial haemorrhages. We describe the case of an adult patient with an atherosclerotic Moya-Moya disease which presented with a cerebral borderzone infarction.
- Published
- 2007
- Full Text
- View/download PDF
46. Cryptogenic cerebral infarction in a young patient with very high lipoprotein(a) serum level as the only risk factor.
- Author
-
Lentini A, Fornengo P, Bosco G, Caprioli M, Destefanis E, and Cerrato P
- Subjects
- Adult, Cerebral Infarction pathology, Humans, Magnetic Resonance Imaging, Male, Cerebral Infarction blood, Lipoprotein(a) blood, Risk Factors
- Abstract
Lipoprotein(a) [Lp(a)] is a plasma lipoprotein that consists of a low-density lipoprotein (LDL)-like particle containing APO B-100 and apolipoprotein(a), linked by a disulphide bridge. There is evidence that higher serum level of Lp(a) is a predictor of various vascular diseases, such as myocardial infarction, coronary stenosis, re-occlusion of aortocoronary bypass vein grafts, peripheral atherosclerosis and cerebral infarction [1-4]. We describe a young man with a cryptogenic stroke with very high serum level of Lp(a) as the only vascular risk factor.
- Published
- 2007
- Full Text
- View/download PDF
47. Recurrent cerebrovascular ischaemic events in patients with interatrial septal abnormalities: a follow-up study.
- Author
-
Cerrato P, Priano L, Imperiale D, Bosco G, Destefanis E, Villar AM, Ribezzo M, Trevi GP, Bergamasco B, and Orzan F
- Subjects
- Adolescent, Adult, Echocardiography methods, Female, Follow-Up Studies, Humans, Male, Middle Aged, Proportional Hazards Models, Recurrence, Retrospective Studies, Survival Analysis, Heart Aneurysm complications, Heart Septal Defects, Atrial complications, Ischemic Attack, Transient complications, Risk
- Abstract
The aim of this study was to evaluate the risk of recurrent ischaemic cerebrovascular events (stroke or transient ischaemic attack (TIA)) in patients with patent foramen ovale (PFO) or atrial septal aneurysm (ASA) treated with different therapeutic regimens. We enrolled 86 patients aged 18-60 years with an unexplained ischaemic stroke or TIA referred to our inpatient department in the period May 1994-December 1999. Follow-up lasted until April 2003. Patients were excluded if the stroke or TIA was related to large-artery atherosclerosis, small artery occlusion, major cardiac sources of embolism or other uncommon causes. During a follow-up (mean+/-SD) of 64.1+/-28.8 months (range 8.1-105.6) a recurrent ischaemic cerebrovascular event occurred in 11/86 patients (12.8%) (5 TIA and 6 strokes). Eight events (4 TIA, 4 strokes) occurred in the 59 patients with PFO alone, three (1 TIA, 2 strokes) in the 21 with PFO plus ASA and none in the 6 patients with ASA alone. In the overall population the cumulative risk of recurrent stroke/TIA was 1.2% at 2 years, 5.5% at 4 years, 7.6% at 6 years and 23.6% at 8 years, and was similar in patients with PFO alone vs. patients with PFO plus ASA (9.0% vs. 6.1% at 6 years, 26.0% vs. 23.1% at 8 years; p>0.05). Nine cerebral ischaemic events (4 TIA, 5 strokes) occurred in the 48 patients treated with antiplatelet drugs (7 in patients with PFO, 2 in patients with PFO plus ASA), and two (1 TIA, 1 stroke) in the 17 patients treated with oral anticoagulants (1 with PFO, 1 with PFO plus ASA). No events occurred in patients submitted to transcatheteral closure.
- Published
- 2006
- Full Text
- View/download PDF
48. Hypogeusia and hearing loss in a patient with an inferior collicular infarction.
- Author
-
Cerrato P, Lentini A, Baima C, Grasso M, Azzaro C, Bosco G, Destefanis E, Benna P, Bergui M, and Bergamasco B
- Subjects
- Ageusia diagnosis, Ageusia physiopathology, Ataxia etiology, Ataxia physiopathology, Brain Ischemia diagnosis, Brain Ischemia physiopathology, Brain Stem pathology, Brain Stem physiopathology, Brain Stem Infarctions diagnosis, Brain Stem Infarctions physiopathology, Face innervation, Face physiopathology, Hearing Loss, Central diagnosis, Hearing Loss, Central physiopathology, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Neural Pathways pathology, Neural Pathways physiopathology, Sensation Disorders etiology, Sensation Disorders physiopathology, Tomography, X-Ray Computed, Tongue innervation, Tongue physiopathology, Trigeminal Nerve Diseases etiology, Trigeminal Nerve Diseases physiopathology, Vertebrobasilar Insufficiency diagnosis, Vertebrobasilar Insufficiency physiopathology, Ageusia etiology, Brain Ischemia complications, Brain Stem Infarctions complications, Hearing Loss, Central etiology, Inferior Colliculi pathology, Inferior Colliculi physiopathology
- Published
- 2005
- Full Text
- View/download PDF
49. [Complement power and its fractions in the cerebrospinal fluid in tuberculous meningitis].
- Author
-
CASTELLI D and DESTEFANIS E
- Subjects
- Humans, Cerebrospinal Fluid, Tuberculosis, Tuberculosis, Meningeal cerebrospinal fluid
- Published
- 1956
50. [First clinical observations on the antituberculous activity of a compound derived from the salification of streptomycin and Congo red].
- Author
-
PESCETTI G and DESTEFANIS E
- Subjects
- Humans, Aniline Compounds therapeutic use, Coloring Agents therapeutic use, Congo Red, Streptomycin therapeutic use, Tuberculosis, Tuberculosis, Meningeal therapy, Tuberculosis, Pulmonary therapy
- Published
- 1953
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.